BioCentury
ARTICLE | Company News

Boehringer eyeing NASH space with Pharmaxis option

March 14, 2015 2:12 AM UTC

Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) an exclusive option to acquire worldwide rights to PXS4728A. According to Pharmaxis, Boehringer is interested in developing the compound to treat non-alcoholic steatohepatitis (NASH). The oral vascular adhesion protein-1 (VAP-1; SSAO) inhibitor is in Phase I testing for inflammatory disease, with data expected in 3Q15. ...